Tenon Medical, Inc. (TNON) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings, and welcome to the Tenon Inc. Second Quarter 2025 Earnings Conference Call. At this time, all assistance is in only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator's assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Stephen Foster, CEO and President. Thank you. You may begin. Thank you, Maria, and good afternoon, everyone. I'm pleased to welcome you to today's second quarter 2025 financial results and corporate update conference call for Tenon Medical. We recently marked a pivotal step forward for Tenon Medical, highlighted by a strategic acquisition on top of a second quarter that included continued clinical validation and meaningful progress towards diversification of our product offerings. Speaking to our recent announcement, a significant focus of our second quarter initiatives was the thorough due diligence and successful completion of the strategic acquisition of SciVantage, which we announced subsequent to quarter end. With integration to take place over the next 60 to 90 days, this transaction delivers active case value, revenue generating technologies, and a robust pipeline that will continue to scale. The deal significantly enhances our commercial organization, It unlocks new pathways through hospital approval processes, distribution networks, and market access. Importantly, the transaction energizes our commercial infrastructure in the tools and talent to drive sustainable top-line growth. In tandem, we continue to advance the CatamRAM platform with real-world adoption in complex fine procedures. Dr. Andrew Trontis completed initial catamaran cases demons...